Curing Death
  Recent News |  Archives |  Tags |  About |  Newsletter |  Submit News |  Advertise With Us |  Subscribe to CuringDeath.com RSS Fee Subscribe

Researchers Find New Superbug Weapon for Failing Antibiotics Arsenal (3/27/2007)

Tags:
antibiotics, infection, bacteria, mrsa

Imagine the desperation of trying to fight lethal infections when antibiotics fail to work.

That scenario -- commonly found with "hospital superbugs" -- may well improve thanks to a discovery by a research team at the University of British Columbia, in collaboration with UBC spin-off company Inimex Pharmaceuticals, that has identified a peptide that can fight infection by boosting the body's own immune system.

"Antibiotics are now under threat because of the explosion in antibiotic-resistant bacteria. A third of all deaths on this planet are the result of infection so there is an urgent need to create new therapies," says Robert Hancock, principal investigator and Canada Research Chair in Pathogenomics and Antimicrobials. "The beauty of this peptide is that it acts on the host to trigger a protective response and doesn't act on bacteria directly. That means it's unlikely bacteria will become resistant to it."

The team found that a peptide, or chain of amino acids, they have dubbed innate defense regulator peptide (IDR-1), can increase innate immunity without triggering harmful inflammation, and offer protection both before and after infection is present.

The discovery, in animal models, will be published March 25 in the journal Nature Biotechnology.

Researchers tested the peptide's effectiveness against Staphylococcus aureus including MRSA; a superbug called vancomycin-resistant Enterococcus (VRE); and Salmonella. In Staph and VRE infections, although bacteria were not completely eradicated, IDR-1 significantly reduced bacteria counts and mortality, when given either 24-48 hours before or four hours after infection began. In Salmonella, the peptide offered significant protection when administered prior to infection setting in.

Data showed that IDR-1 activates several signaling pathways to stimulate infection-clearing chemokines -- a chemical mediator that mobilizes immune response.

In addition, the peptide did not produce harmful inflammation and toxicity often seen when the immune system is stimulated and, in fact, actually reduced the potentially harmful septic response. Sepsis, a consequence of a ravaging inflammatory response associated with infection, kills as many as 200,000 annually.

The innate immune response is the first line of defense against infection and comprises an interactive network of cellular and molecular systems that recognize and kill pathogens, as well as signaling pathways that trigger biological responses.

The researchers anticipate the therapy may be useful as a supplement to antibiotics in combating common hospital infections such as ventilator associated pneumonia, post-surgical infections, high dose chemotherapy and infections arising from insertion of catheters or other medical devices.

"We now have a powerful new tool that will allow us to stop infection before it starts -- it's a new concept in treating infection," says Hancock.

The researchers estimate there are two million cases of antibiotic-resistant infection in hospitals that kill approximately 70,000 people annually in North America. Hospital-based methicillin-resistant Staphylococcus aureus (MRSA) alone causes an estimated 100,000 hard-to-treat infections annually and is now seen in community-based infections, such as boils and abscesses or life-threatening bloodstream infections.

"Salmonella causes 1.3 million infections and up to 100 deaths every year in the U.S. We're looking at a crisis in 10 years as most bugs will be resistant to most antibiotics. There's an urgent need to develop new tools," says Brett Finlay, a UBC microbiologist and an author on the paper. He and Hancock co-founded Inimex, which conducted many of the experiments required for the study.

Researchers expect it will be about 12-15 months before the discovery is introduced into human clinical trials.

"This study provides important insights into how we can fight infection by harnessing the body's own immune system," said Dr. Bhagirath Singh, Scientific Director of the Canadian Institutes of Health Research (CIHR) Institute of Infection and Immunity. "The work of Dr. Hancock and his research team and Inimex collaborators may help develop new treatments and approaches for the prevention of bacterial infections while minimizing the risk of antibiotic resistance."

Support for the research has been provided by CIHR, Canada's major agency responsible for funding health research, and the Foundation for the National Institutes of Health through the Grand Challenges in Global Health Initiative, a U.S.-based project funded by the Bill & Melinda Gates Foundation, that has offered research grants totaling $436.6 million to achieve scientific breakthroughs against lethal diseases in the world's poorest countries.

Additional support has been provided by Genome Canada and Genome BC. Genome Canada is the primary funding and information resource relating to genomics and proteomics research in Canada. It has established six genome centres across the country, including Genome BC.

Inimex Pharmaceuticals, Inc. is a privately held biopharmaceutical company focused on development and commercialization of Innate Defense Regulator products, novel first-in-class drugs that selectively trigger the body's innate defenses without causing inflammation.

CIHR's mission is to create new scientific knowledge and to catalyze its translation into improved health, more effective health services and products, and a strengthened Canadian health care system. Composed of 13 Institutes, CIHR provides leadership and support to more than 10,000 health researchers and trainees across Canada.

Note: This story has been adapted from a news release issued by the University of British Columbia

Comments:

1. Steven Baumeister

3/28/2007 5:30:49 PM MST

The study of immunology has been passed over, industry wide, in favor of more glamorous pursuits for many years. Treatments for viruses and bacteria have focused on the viruses and bacteria themselves rather than focusing on the reasons why the bodies' own immune system is incapable of keeping up. Treatments for cancer, similarly, have focused on the tumors rather than understanding why the immune system has failed to remove the damaged cells. Treatments for neurodegenerative disorders are commonly held to be dysfunctions within those groups of neurons when the data also support the theory that an overzealous immune system is improperly clearing the plaques. Prion diseases are almost always talked about as an accumulation of a misshapen prion protein when, again, the data could also support the theory that the misshapen protein is perfectly normal and it is the immune system which has incorrectly allowed it to accumulate.

Great work by CIHR and Inimex on pursuing a novel approach which concentrates on augmenting, not ignoring or replacing, the bodies' already comprehensive system for dealing with intruders and malfunctions.


2. Cite Your Sources

3/28/2007 10:53:00 PM MST

C'mon guys.

http://www.publicaffairs.ubc.ca/media/releases/2007/mr-07-030.html?src=ubcca


3. Leopold Puzis

3/29/2007 4:36:22 AM MST

Regular information: 1/ To scary people by number of deaths caused by different infections.
2/ To tell how much money spent for a research with reminding names of couple persons in important positions.
3/ Promising how grate and innovative this finding that resolve all problems in a closest future.
My name is Dr. Leopold Puzis. I am Ph.D. in Virology. Perfectly understand how important to have the peptide, or compound, or anything like that described. However even this short communication is enough to understand that these promises have a short life. I will be happy to discuss the published information and to present the results of my study in any auditorium. My email address is l.puzis@med.miami.edu.


4. Peter Gardener

3/29/2007 12:16:51 PM MST

Bactiaphages were a good shot , lets face it , the biggest bug in the system is the rockefeller institute , the drug co's are driven by profit only , they are only interested in producing drugs that partially work , anything that has been proven over time is conveniately labelled " homiopathic " does anyone remember Prof Luigi Di Bella ? we did a broadcast for CNN and the audience was full of those stooges to dispute everything he said , makes sense i guess when $4 billion R&D was being spent on chemo every year
reg Peter


Leave a Reply:

Search
New Articles
Treatments to slow aging and stymie chronic disease in older adults on the horizon

Scientists discover an on-off switch for aging cellsScientists discover an on-off switch for aging cells

Calico enters into exclusive collaboration with 2M to develop UTSW technology

Less effective DNA repair process takes over as mice age

Biologists delay the aging process by 'remote control'Biologists delay the aging process by 'remote control'

Curb sitting time to protect aging DNA and possibly extend lifespan

Researching fundamental rhythms of life

APOB, a gene involved in lipid transport, linked to cases of familial extreme longevity

Are you as old as what you eat? Researchers learn how to rejuvenate aging immune cells

Taking the pulse of aging

Analysis of African plant reveals possible treatment for aging brainAnalysis of African plant reveals possible treatment for aging brain

The 'memory' of starvation is in your genes

Key to aging immune system is discoveredKey to aging immune system is discovered

Strategy proposed for preventing diseases of agingStrategy proposed for preventing diseases of aging

Scientists identify gene that plays a surprising role in combating agingScientists identify gene that plays a surprising role in combating aging



Archives
October 2014
September 2014
August 2014
July 2014
June 2014
May 2014
April 2014
March 2014
February 2014
January 2014
December 2013
November 2013
October 2013
September 2013
August 2013
July 2013
June 2013
May 2013
April 2013
March 2013
February 2013
January 2013
December 2012
November 2012
October 2012
September 2012
July 2012
June 2012
May 2012
April 2012
March 2012
February 2012
January 2012
December 2011
November 2011
October 2011
September 2011
August 2011
July 2011
June 2011
May 2011
April 2011
March 2011
February 2011
January 2011
December 2010
November 2010
October 2010
September 2010
August 2010
July 2010
June 2010
May 2010
April 2010
March 2010
February 2010
January 2010
December 2009
November 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
November 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007
April 2007
March 2007
February 2007
January 2007
December 2006
November 2006
October 2006
August 2006
June 2006
April 2006


Science Friends
Agricultural Science
Astronomy News
Sports Medicine
Biology News
Biomimicry Science
Cognitive Research
Chemistry News
Tissue Engineering
Cybernetics Research
Forensics Report
Fossil News
Electonics Research
Genetic Archaeology
Genetics News
Geology News
Microbiology Research
Nanotech News
Parenting News
Physics News


  Archives |  Submit News |  Advertise With Us |  Contact Us |  Links
Use of this site constitutes acceptance of our Terms of Service and Privacy Policy. All contents © 2000 - 2015 Web Doodle, LLC. All rights reserved.
Web Doodle, LLC does not provide medical advice, diagnosis or treatment. Please read our disclaimer